Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 versus enalapril for exercise capacity in heart failure with reduced ejection fraction
2015-004632-35Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF) comparing sacubitril/valsartan arm with enalapril arm (2 arms). Primary endpoint: Change in peak oxygen consumption adjusted to body weight from baseline after 3 months of treatment. Started Feb 2016; status: completed.
02
Drugs
sacubitril + valsartanenalapril
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2015-004632-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004632-35.